Navigation Links
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
Date:3/8/2011

OMAHA, Neb., March 8, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced the following Webcast:What:

Transgenomic, Inc. Fourth Quarter 2010 Financial Results and Business Update Conference CallWhen:

Friday, March 11, 2011 @ 11:00 a.m. EasternWhere:

http://www.transgenomic.com/events.asp?id=6How:

Live over the Internet -- Simply log on to the web at the address above.Contact:

Investor Relations, 402-452-5400 To access the call via telephone, call 800-895-1715 from the U.S. or Canada or 785-424-1059 for international participants and enter conference ID TRANS.  A telephone replay will be available from 1:00 p.m. Eastern Time March 11, 2011 through 11:59 p.m. Eastern Time on March 25, 2011 by dialing 800-723-0528 (domestic) or 402-220-2654 (international).

About Transgenomic, Inc.Transgenomic, Inc. (www.transgenomic.com ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification.  With broad applicability to genetic research, nearly 1,500 systems have been shipped to customers in more than 50 countries. The SURVEYOR® Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA.  HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.  In December of 2010, we acquired another CLIA certified laboratory in New Haven, Connecticut which specializes in genetic disorders associated with cardiomyopathies and channelopathies.  We believe there is a significant opportunity for us to continue growing the demand for molecular-based testing by leveraging our technologies, experience and expertise in biomarker analysis. In addition, we continue to seek out and evaluate new technologies and new laboratory tests which will further extend our offerings in our Molecular Diagnostics Laboratory and our Pharmacogenomics Services Lab.


'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
2. Transgenomic Reports Third Quarter Financial Results
3. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
4. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
5. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
6. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
7. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
8. Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
9. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
10. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
11. Transgenomic, Inc. Reports Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Genetics Center (RGC), U.K. Biobank and GSK to generate genetic ... Biobank resource. The initiative will enable researchers to gain valuable ... for a wide range of serious and life threatening diseases. ... Genetic ...
(Date:3/22/2017)... COPENHAGEN, Denmark , March 22, 2017 /PRNewswire/ ... that utilizes its innovative TransCon technology to address ... announced financial results for the full year ended ... a significant year for our company as we ... become a leading, integrated rare disease company with ...
(Date:3/22/2017)... Mass. , March 22, 2017 Good ... that it has eclipsed the 130 million covered lives ... Blue Shield of Texas . With ... the Company continues to enjoy strong payor acceptance based ... its clinical programs and genetic counseling, its industry-leading customer ...
Breaking Biology Technology:
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):